STAAR Surgical Company, a global leader in phakic IOLs for vision correction, has released its latest investor presentation. The document highlights the company's approach to addressing the myopia epidemic, presenting key financial measures such as Adjusted EBITDA to evaluate operating performance. The presentation notes STAAR's efforts to mitigate foreign currency effects by offering financial information on a constant currency basis. Additionally, it emphasizes the benefits of their EVO technology, which preserves the tear film and cornea without inducing dry eye or requiring tissue removal. STAAR Surgical boasts a strong global presence, with significant market share in Japan, and outlines its strategy for accelerating growth through macroeconomic recovery and market expansion. You can access the full presentation through the link below.